Tonix Pharmaceuticals Holding annual gross margin
2023
2024
2025
Tonix Pharmaceuticals Holding Gross Margin Growth & History (TNXP)
Tonix Pharmaceuticals Holding's gross margin was 49.34% for fiscal 2025.
View full Tonix Pharmaceuticals Holding company overviewTonix Pharmaceuticals Holding annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 49.34% | +26.27 pp |
| 2024 | 2024-12-31 | 23.07% | −15.89 pp |
| 2023 | 2023-12-31 | 38.97% | — |
Tonix Pharmaceuticals Holding quarterly gross margin
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 94.81% | +158.57 pp |
| Q1 2026 | 2026-03-31 | 77.06% | +15.88 pp |
| Q4 2025 | 2025-12-31 | 80.37% | +26.19 pp |
| Q3 2025 | 2025-09-30 | 58.45% | +13.55 pp |
| Q2 2025 | 2025-06-30 | −63.76% | −11.27 pp |
| Q1 2025 | 2025-03-31 | 61.18% | +28.06 pp |
| Q4 2024 | 2024-12-31 | 54.18% | — |
| Q3 2024 | 2024-09-30 | 44.90% | +4.41 pp |
| Q2 2024 | 2024-06-30 | −52.49% | — |
| Q1 2024 | 2024-03-31 | 33.12% | — |
| Q3 2023 | 2023-09-30 | 40.49% | — |
Tonix Pharmaceuticals Holding gross margin trends
Between the periods ended 2023-12-31 and 2025-12-31, Tonix Pharmaceuticals Holding's gross margin increased from 38.97% to 49.34%, a change of +10.37 percentage points. The latest reported quarter, Q2 2026, shows 94.81%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tonix Pharmaceuticals Holding source filings ↗